[우리카지노 바카라사이트 USA] K-우리카지노 바카라사이트 showcases in Boston, the U.S. 우리카지노 바카라사이트 hub…“Pursuing global partnership expansion”

[by Ji, Yong Jun] A line extending over 30 meters formed in front of the Boston Convention & Exhibition Center in Massachusetts, USA, as global pharmaceutical and biotechnology industry professionals from around the world gathered on the morning of June 16 (local time) to attend the ‘BIO International Convention 2025 (BIO USA)’ in Boston, widely recognized as the world’s largest biotechnology hub.

Over the four-day duration of 우리카지노 바카라사이트 USA, more than 1,100 experts are expected to engage in in-depth discussions across key areas of 우리카지노 바카라사이트technology, including artificial intelligence (AI), digital healthcare, next-generation 우리카지노 바카라사이트therapeutics, and business development (BD). The event has drawn a substantial number of participants not only from the United States but also from the global pharmaceutical and 우리카지노 바카라사이트technology sectors, contributing to its vibrant atmosphere. According to estimates by the organizing body, the 우리카지노 바카라사이트technology Innovation Organization (우리카지노 바카라사이트), representatives from 72 countries are in attendance, with international participants accounting for 46% of the over 20,000 total attendees.

According to a representative from a Korean 우리카지노 바카라사이트tech firm, the 우리카지노 바카라사이트 USA convention, once predominantly led by global pharmaceutical companies, has undergone a shift in focus. Today, the primary participants are business development teams, university research groups, national research institutions, and government agencies. This reflects a broader transformation of the event from a platform primarily for corporate promotion to a strategic hub for fostering connections in the global research and innovation ecosystem.

Notably, Chinese companies that had boycotted BIO USA last year have resumed their participation. “There is a growing trend of Chinese biotech companies gradually rejoining BIO USA,” said Lee Seung-gyu, Vice Chairman of the Korea Biotechnology Industry Organization (KoreaBIO).

This year, a significant number of participants from Korea’s pharmaceutical and biotechnology sector, ranging from large corporations to startups, attended the BIO USA event. According to the Korea Biotechnology Industry Organization (KoreaBIO), approximately 60 Korean companies took part, including major firms such as Samsung Biologics, Celltrion, SK Biopharmaceuticals, and Lotte Biologics, which operated individual booths. Additionally, 51 companies showcased their technologies through the ‘Korean Pavilion,’ jointly organized by KoreaBIO and KOTRA.

Samsung Biologics, the only Korean company to have maintained a standalone booth at BIO USA for 13 consecutive years since its founding in 2011, drew attention by installing a 167 m2 booth at the heart of the exhibition hall’s busiest area. This year, in addition to highlighting its global competitiveness in securing orders, the company unveiled ‘Samsung Organoids,’ a newly launched organoid-based drug screening service that marks its expansion into clinical trial contract research organization (CRO) services. “This year, our focus was on promoting organoid services and antibody-drug conjugate (ADC) capabilities,” expressed James Choi, Vice President of Samsung Biologics.

Celltrion is operating a standalone booth of approximately 140 m2 at 우리카지노 바카라사이트 USA, facilitating contact with numerous global companies through open meeting areas and private conference rooms. The company anticipates holding over 100 meetings during the event. In addition to promoting its established 우리카지노 바카라사이트similar portfolio, Celltrion aims to explore partnerships for pipeline expansion, with a strategic focus on next-generation ADCs and novel antibody drugs.

SK Biopharmaceuticals set up its first standalone booth at the event, placing emphasis on showcasing its novel drug development capabilities through its epilepsy drug, ‘XCOPRI (cenobamate).’ “Through BIO USA, we aim to reaffirm our company’s innovative novel drug development capabilities and global partnership expansion strategy,” stated Choi Yoon-jung, head of SK Biopharmaceuticals’ business development division. “This year, we intend to pursue more concrete collaborative opportunities and further solidify our position within the global healthcare ecosystem.”

Shin Yoo-yeol, vice President of Lotte Holdings and third-generation heir of the Lotte Group, garnered attention by attending the event alongside Lotte 우리카지노 바카라사이트logics CEO James Park. Shin and Park personally visited the Korean pavilion, where Korean companies were gathered, and emphasized the importance of expanding partnerships in the field of ADCs.

Major affiliates of Dong-A Socio Holdings, including Dong-A ST, ST Pharm, and STgen Bio, also participated with a joint booth, concentrating on promoting their respective competitive strengths. Kyongbo Pharmaceutical, an affiliate of Chong Kun Dang pharmaceutical, signaled its intention for global expansion by introducing ADC CDMO capabilities at this year’s BIO USA.

Korean biotechnology companies also placed a strong emphasis on business development (BD) by actively promoting their technologies through one-on-one meetings, rather than operating exhibition booths. During a press conference hosted by the KoreaBIO on the same day, Vice Chairman Lee Seung-gyu emphasized, “Whereas last year’s focus was primarily on modality (treatment approaches), this year saw participation not only from companies but from across all segments of the biotechnology and healthcare industries,” adding, “The global community is increasingly recognizing the importance of the biotech industry.”